INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS

被引：1
|
作者：
Rousseau, B. [1 ]
Poinas, A. [1 ]
Oliver, L. [1 ]
Collings, H. [1 ]
机构：
[1] Adelphi Values Ltd, Bollington, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1787
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP251
引用
收藏
页码：A695 / A696
页数：2
相关论文
共 50 条
  • [31] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [32] Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
    Jakubowski, Szczepan
    Kawalec, Pawel
    Holko, Przemyslaw
    Kowalska-Bobko, Iwona
    Kamusheva, Maria
    Petrova, Guenka
    Draganic, Pero
    Fuksa, Leos
    Mannik, Agnes
    Ispan, Fanni
    Briedis, Vitalis
    Bianchi, Ioana
    Paveliu, Marian Sorin
    Tesar, Tomas
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [33] Orphan drugs: The European perspective
    Stathopoulos, Georgios
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 34 - 34
  • [34] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Kolasa, Katarzyna
    Zwolinski, Krzysztof M.
    Kalo, Zoltan
    Hermanowski, Tomasz
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [35] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Katarzyna Kolasa
    Krzysztof M. Zwolinski
    Zoltan Kalo
    Tomasz Hermanowski
    [J]. Orphanet Journal of Rare Diseases, 11
  • [36] The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
    Bang, Joon Seok
    Lee, Jong Hyuk
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (04): : 105 - 112
  • [37] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    [J]. VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [38] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    [J]. Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [39] ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES: EUROPEAN AND AUSTRALIAN PAYER PERCEPTIONS
    Hogue, S.
    Brogan, A. P.
    Croft, E.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A681 - A681
  • [40] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Denis, Alain
    Mergaert, Lut
    Fostier, Christel
    Cleemput, Irina
    Hulstaert, Frank
    Simoens, Steven
    [J]. PHARMACOECONOMICS, 2011, 29 (10) : 883 - 893
12345